Heart valve repair may unlock higher doses of key heart failure drugs
NCT ID NCT07578129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 50 people with severe tricuspid regurgitation (a leaky heart valve) and reduced heart function who undergo valve repair using the PASCAL Precision System. The main goal is to see if, 12 months after repair, patients can take higher doses of standard heart failure medications compared to before the procedure. Researchers will also track hospitalizations and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PASCAL Precision System (device for tricuspid valve repair)
What this could lead to
If successful, this could show that repairing the tricuspid valve helps heart failure patients tolerate higher doses of guideline-directed medications, potentially improving outcomes.
What could go wrong
This is a small, early observational study (50 people) with no control group. It only measures medication changes, not direct health improvements, so results may not be conclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••